Cargando…
Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes
A paradox in monoclonal antibody (mAb) therapy is that despite the well-documented tolerogenic properties of deaggregated IgG, most therapeutic IgG mAb induce anti-mAb responses. To analyze CD4 T cell reactions against IgG in various physical states, we developed an adoptive transfer model using CD4...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256993/ https://www.ncbi.nlm.nih.gov/pubmed/28114383 http://dx.doi.org/10.1371/journal.pone.0170556 |
_version_ | 1782498791177322496 |
---|---|
author | St. Clair, J. Benjamin Detanico, Thiago Aviszus, Katja Kirchenbaum, Greg A. Christie, Merry Carpenter, John F. Wysocki, Lawrence J. |
author_facet | St. Clair, J. Benjamin Detanico, Thiago Aviszus, Katja Kirchenbaum, Greg A. Christie, Merry Carpenter, John F. Wysocki, Lawrence J. |
author_sort | St. Clair, J. Benjamin |
collection | PubMed |
description | A paradox in monoclonal antibody (mAb) therapy is that despite the well-documented tolerogenic properties of deaggregated IgG, most therapeutic IgG mAb induce anti-mAb responses. To analyze CD4 T cell reactions against IgG in various physical states, we developed an adoptive transfer model using CD4+ T cells specific for a Vκ region-derived peptide in the hapten-specific IgG mAb 36–71. We found that heat-aggregated or immune complexes (IC) of mAb 36–71 elicited anti-idiotypic (anti-Id) antibodies, while the deaggregated form was tolerogenic. All 3 forms of mAb 36–71 induced proliferation of cognate CD4+ T cells, but the aggregated and immune complex forms drove more division cycles and induced T follicular helper cells (T(FH)) development more effectively than did the deaggregated form. These responses occurred despite no adjuvant and no or only trace levels of endotoxin in the preparations. Physical analyses revealed large differences in micron- and nanometer-sized particles between the aggregated and IC forms. These differences may be functionally relevant, as CD4+ T cell proliferation to aggregated, but not IC mAb 36–71, was nearly ablated upon peritoneal injection of B cell-depleting antibody. Our results imply that, in addition to denatured aggregates, immune complexes formed in vivo between therapeutic mAb and their intended targets can be immunogenic. |
format | Online Article Text |
id | pubmed-5256993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-52569932017-02-06 Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes St. Clair, J. Benjamin Detanico, Thiago Aviszus, Katja Kirchenbaum, Greg A. Christie, Merry Carpenter, John F. Wysocki, Lawrence J. PLoS One Research Article A paradox in monoclonal antibody (mAb) therapy is that despite the well-documented tolerogenic properties of deaggregated IgG, most therapeutic IgG mAb induce anti-mAb responses. To analyze CD4 T cell reactions against IgG in various physical states, we developed an adoptive transfer model using CD4+ T cells specific for a Vκ region-derived peptide in the hapten-specific IgG mAb 36–71. We found that heat-aggregated or immune complexes (IC) of mAb 36–71 elicited anti-idiotypic (anti-Id) antibodies, while the deaggregated form was tolerogenic. All 3 forms of mAb 36–71 induced proliferation of cognate CD4+ T cells, but the aggregated and immune complex forms drove more division cycles and induced T follicular helper cells (T(FH)) development more effectively than did the deaggregated form. These responses occurred despite no adjuvant and no or only trace levels of endotoxin in the preparations. Physical analyses revealed large differences in micron- and nanometer-sized particles between the aggregated and IC forms. These differences may be functionally relevant, as CD4+ T cell proliferation to aggregated, but not IC mAb 36–71, was nearly ablated upon peritoneal injection of B cell-depleting antibody. Our results imply that, in addition to denatured aggregates, immune complexes formed in vivo between therapeutic mAb and their intended targets can be immunogenic. Public Library of Science 2017-01-23 /pmc/articles/PMC5256993/ /pubmed/28114383 http://dx.doi.org/10.1371/journal.pone.0170556 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article St. Clair, J. Benjamin Detanico, Thiago Aviszus, Katja Kirchenbaum, Greg A. Christie, Merry Carpenter, John F. Wysocki, Lawrence J. Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes |
title | Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes |
title_full | Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes |
title_fullStr | Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes |
title_full_unstemmed | Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes |
title_short | Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes |
title_sort | immunogenicity of isogenic igg in aggregates and immune complexes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256993/ https://www.ncbi.nlm.nih.gov/pubmed/28114383 http://dx.doi.org/10.1371/journal.pone.0170556 |
work_keys_str_mv | AT stclairjbenjamin immunogenicityofisogenicigginaggregatesandimmunecomplexes AT detanicothiago immunogenicityofisogenicigginaggregatesandimmunecomplexes AT aviszuskatja immunogenicityofisogenicigginaggregatesandimmunecomplexes AT kirchenbaumgrega immunogenicityofisogenicigginaggregatesandimmunecomplexes AT christiemerry immunogenicityofisogenicigginaggregatesandimmunecomplexes AT carpenterjohnf immunogenicityofisogenicigginaggregatesandimmunecomplexes AT wysockilawrencej immunogenicityofisogenicigginaggregatesandimmunecomplexes |